Dr. Snyder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-359-8111Fax+1 626-218-5310
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1980
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
Harvard Medical SchoolClass of 1977
Certifications & Licensure
CA State Medical License 1984 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- 402 citationsLate mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor studySmita Bhatia, Liton Francisco, Andrea Carter, Can Lan Sun, K. Scott Baker
Blood. 2007-11-15 - 64 citationsAssociation of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Raju Pillai, James F. Sanchez, Matthew Mei
American Journal of Hematology. 2019-10-01 - 76 citationsBone marrow transplantation for myelodysplastic and myeloproliferative syndromes.M R O'Donnell, A P Nademanee, David S. Snyder, G M Schmidt, Pablo M. Parker
Journal of Clinical Oncology. 1987-11-01
Abstracts/Posters
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative LeadershipDecember 8th, 2020
Imetelstat Promising Across Myeloproliferative NeoplasmsSeptember 4th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
